BRIEF published on 01/08/2025 at 14:35, 10 months 27 days ago Health Canada Approves Formycon's Biosimilar FYB202/Otulfi® Healthcare Costs Biosimilar Formycon Ustekinumab Canada Approval
PRESS RELEASE published on 01/08/2025 at 14:30, 10 months 27 days ago Formycon and Fresenius Kabi Canada receive Health Canada’s approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Formycon and Fresenius Kabi Canada obtain Health Canada's approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara® Health Canada Approval Biosimilar Formycon Stelara Fresenius Kabi Canada
BRIEF published on 12/11/2024 at 16:31, 11 months 24 days ago Formycon AG Maintains Strong Growth Prospects Amidst Challenging Market Conditions FDA Approval Revenue Decline Formycon AG Biosimilars Stelara Launch
PRESS RELEASE published on 12/11/2024 at 16:26, 11 months 24 days ago Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research publishes update on Formycon AG with BUY rating and EUR 82.00 price target, highlighting decline in revenue and upcoming biosimilar launches First Berlin Equity Research BUY Rating Formycon AG EUR 82.00 Price Target Biosimilar Launches
BRIEF published on 12/09/2024 at 06:35, 11 months 27 days ago MS Pharma to Commercialize FYB202 in MENA MENA Region Formycon AG Biosimilars MS Pharma FYB202
PRESS RELEASE published on 12/09/2024 at 06:30, 11 months 27 days ago MS Pharma becomes Partner for the Commercialization of FYB202 / ustekinumab in the MENA Region Formycon AG and MS Pharma sign licensing and supply agreement for the commercialization of FYB202/ustekinumab biosimilar in MENA region, expanding patient access to vital treatments MENA Region Formycon AG MS Pharma FYB202 Ustekinumab
BRIEF published on 12/05/2024 at 13:00, 11 months 30 days ago Formycon Joins the SDAX of the German Stock Exchange Market Strategy Biosimilars SDAX Formycon German Stock Exchange
PRESS RELEASE published on 12/05/2024 at 12:55, 11 months 30 days ago Formycon joins the SDAX of the German Stock Exchange Formycon AG joins the SDAX of the German Stock Exchange, enhancing share attractiveness and visibility in the capital market. Key milestone in the company's growth strategy Formycon AG Biosimilars Capital Market SDAX German Stock Exchange
BRIEF published on 11/28/2024 at 06:35, 1 year ago Formycon Reports Continued Growth in 2024 Nine-Month Results Financial Results Market Position FDA Approval Biosimilars Strategic Growth
PRESS RELEASE published on 11/28/2024 at 06:30, 1 year ago Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes Formycon reports nine-month results for 2024 with operational successes and growth trajectory, including product approvals and new biosimilar candidates Biosimilars Growth Trajectory Formycon Nine-month Results Operational Successes
Published on 12/05/2025 at 02:35, 8 hours 27 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 10 hours 2 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 11 hours 57 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 12 hours 2 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 10:30, 32 minutes ago Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 46 minutes ago Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 1 hour 21 minutes ago Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration
Published on 12/05/2025 at 09:30, 1 hour 32 minutes ago REPLOID Group AG: Exhibitor at the BIOGAS Convention & Trade Fair in Nuremberg, Germany
Published on 12/05/2025 at 09:05, 1 hour 56 minutes ago Transforming Football: IBM and Bayer 04 Leverkusen Use AI for Superior Game Analysis
Published on 12/05/2025 at 08:45, 2 hours 17 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 17 hours 2 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 17 hours 17 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 17 hours 17 minutes ago Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 4 hours ago bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
